Share This

Found something you'd like to share with a colleague or friend? Fill out the form below to share it.

*Denotes Required Field
*Your name: *Your email:

*Friend's name: *Friend's email:
Optional Message:

This site contains information for licensed healthcare professionals in the United States. By entering this website you acknowledge that you are a licensed healthcare professional in the United States.


You are now leaving

This link is provided as a service to our website visitors, and any information provided on this site is not specific to the use of DigiFab®.

Click "Yes" to proceed to or "No" to return to


Dosing and Storage

DigiFab® Digoxin Immune Fab (Ovine) dosing will vary according to the amount of digoxin or digitoxin to be neutralized. Follow these instructions to determine the proper amount for DigiFab® Digoxin Immune Fab (Ovine) dosing.1

Dosage: Acute Ingestion of Unknown Amount1

Digifab dosage - chart 1

For patients presenting with life-threatening digitalis toxicity caused by an acute ingestion when neither a serum digitalis nor an estimated ingestion amount is available.1

Dosage: Toxicity During Chronic Therapy1

Digifab dosage - chart 2

To reverse most cases of toxicity in adult patients who are in acute distress or for whom a serum digoxin concentration is not available.1

Dosage: Ingestion of Known Amount1

Each vial of DigiFab® Digoxin Immune Fab (Ovine) contains 40 mg of purified digoxin-specific Fab, which will bind approximately 0.5 mg of digoxin.1

Alternative: Use steady-state serum concentration to approximate the total number of vials for adult patients.

Digifab dosage - chart 3


The reconstituted product should be used promptly. If not used, it may be stored under refrigeration at 2° to 8°C (36° to 46°F) for up to 4 hours.1

Read guidelines for administering DigiFab® »

To report an adverse event or for 24-hour medical information, call 1-844-293-0007.

  1. DigiFab® [prescribing information]. BTG International Inc. January 2012.

DigiFab® Digoxin Immune Fab (Ovine) is indicated for the treatment of patients with life-threatening or potentially life-threatening digoxin toxicity or overdose. DigiFab® is not indicated for milder cases of digitalis toxicity.

Important Safety Information
Patients with poor cardiac function may deteriorate secondary to the withdrawal of the inotropic action of digoxin by DigiFab®.  Rapid drop in serum potassium concentration may occur after treatment with DigiFab®. Patients with known allergies to sheep protein, papaya, or papain are at higher risk of an anaphylactic reaction. Suicidal ingestion may involve more than one drug. Toxic effects of other drugs or poisons should not be overlooked. The most common adverse reactions (>7%) related to DigiFab® are worsening congestive heart failure (13%), hypokalemia (13%) and worsening atrial fibrillation (7%). Please see full prescribing information, including events, precautions, or warnings.